Related Experiment Video
Updated: Jun 27, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
The epidemiology of invasive Streptococcus pneumoniae disease in Croatian children
Marija Guzvinec1, Goran Tesović, Arjana Tambić-Andrasević
1University Hospital for Infectious Diseases, Zagreb, Croatia.
Insights
Introducing pneumococcal conjugate vaccines (PCVs) in Croatia could significantly reduce invasive pneumococcal disease (IPD) in children. This study analyzed IPD characteristics and vaccine coverage in Croatian children, highlighting the potential impact of PCVs.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Microbiology
Background:
- Invasive pneumococcal disease (IPD) poses a significant public health challenge in childhood.
- Pneumococcal conjugate vaccines (PCVs) present a promising strategy for reducing IPD incidence.
Purpose of the Study:
- To characterize IPD epidemiology and serotypes in Croatian children.
- To evaluate the potential impact of introducing various PCVs in Croatia.
Main Methods:
- Prospective collection of Streptococcus pneumoniae isolates from children under 14 years old in Croatia (2001, 2005, 2006).
- Analysis of epidemiological data, clinical parameters, serotyping results, and antimicrobial susceptibility.
Main Results:
- 100 IPD strains were analyzed, with 79% from children under five. Highest incidence was in children under two years (33.9/100,000).
- Serotypes 14, 6B, 18C, and 23F were most common (67%). PCV7, PCV10, and PCV13 coverage was 72%, 80%, and 90%, respectively.
- 20% of isolates showed penicillin resistance, and 33.8% showed erythromycin resistance. PCV7 covered 85% of penicillin-resistant and 80% of erythromycin-resistant strains.
Conclusions:
- PCV inclusion in immunization programs can substantially decrease IPD-related illness in Croatian children.
- The findings support the implementation of PCVs to combat childhood IPD in Croatia.
Background:
Invasive pneumococcal disease (IPD) is a major medical problem in childhood. Pneumococcal conjugate vaccines (PCVs) offer a new possibility to reduce the incidence of pneumococcal infections, especially IPD. The aim of this study was to describe the characteristics of IPD among Croatian children and examine the possibilities of introducing different PCVs in our population.
Material/Methods:
Streptococcus pneumoniae isolates causing IPD during three years (2001, 2005, 2006) in Croatian children younger than 14 years old were collected prospectively. Epidemiological and clinical parameters, results of serotyping, and antimicrobial susceptibility data were evaluated.
Results:
One hundred strains were collected during the study period. The ages of the patients ranged from 30 days to 13 years (median: 25.5 months). Seventy-nine percent of the isolates were from patients younger than five years old. The incidence of IPD was highest among children younger than two years of age (33.9/100,000). Serotypes 14, 6B, 18C, and 23F accounted for 67% of all serotypes. The overall coverage rates of PCV7, PCV10, and PCV13 were 72%, 80%, and 90%, respectively. Low-level resistance to penicillin was found in 20% of the isolates and high resistance to erythromycin in 33.8%. PCV7 covered 85% of the penicillin-resistant strains and 80% of the erythromycin-resistant strains.
Conclusions:
The inclusion of a PCV in the immunization program could have a considerable effect on IPD-associated morbidity among Croatian children.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Streptococcal Pharyngitis
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Pneumonia II: Pathophysiology
Respiratory Syncytial Virus Disease
